Hemodynamics and Immune Defense

Discoveries in Pharmacology, Volume 3
2. Auflage 2023
ISBN: 978-0-443-18442-0
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 191 mm x 235 mm, Gewicht: 450 g

Haemodynamics and Immune Defence: Discoveries in Pharmacology, Second Edition, Volume Three presents selected articles from the historic Discoveries in Pharmacology series that are enhanced with commentary from contemporary scholars who discuss the reception and importance of each chapter along with an updated bibliography on the subject and contributions from those involved in Nobel Prize winning discoveries and pioneering advancements in Pharmacology. This volume brings forth discussions on key discoveries in hemodynamics and immune defense, including chapters on penicillin by Dr. Selwyn and asthma by Dr. Brocklehurst.

Academic and industry researchers in pharmacology and medicine, as well as advanced students in the area, will find this useful teaching tool and launch to new discoveries. Chapters can also be used to supplement course material in pharmacology and medical courses. It will also be of interest to those who are interested in the history of medicine.

Autoren/Hrsg.

Parnham, Michael J.

Page, Clive

Bruinvels, Jacques

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie

Inhaltsverzeichnis

1. The control of blood pressure: The discovery of beta adrenoceptor blocking drugs
2. The control of blood pressure: Peripheral anti-hypertensives: ganglion and adrenergic neurone-blocking agents
3. Anti-inflammatory drugs: The proliferation of non-steroidal anti-inflammatory drugs (NSATDS
4. Anti-inflammatory drugs: The story of aspirin
5. The inhibition of allergic reactions: Histamine receptor antagonists
6. The inhibition of allergic reactions: Asthma: a long and continuing story
7. From dyes to drugs
8. The discovery of penicillin and cephalosporins

Über Autor(innen)

Bruinvels, Jacques
Professor Jacques Bruinvels, Ph.D. is Professor Emeritus of Pharmacology, Department of Pharmacology, Erasmus University Rotterdam, Rotterdam, The Netherlands. Full biography to follow

Page, Clive
Professor Clive P. Page, BSc PhD OBE HonFBPhS is a Professor of Pharmacology, King's College London and Director of the Sackler Institute of Pulmonary Pharmacology, King's College London. Clive's main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of and on boards of several companies. He was awarded the Society of Biology President's Medal in 2012 for an outstanding contribution to the life sciences over the previous year. He is a Fellow of the Royal Society of Biology and an Honorary Fellow and President Elect of the British Pharmacological Society. In 2017, Clive was awarded an OBE for Services to Pharmacology.

Parnham, Michael J.
Professor Michael J. Parnham, Ph.D., C.Biol.MRSB, FBPhS studied Pharmacology at Chelsea (now King's) College, gaining practical experience in the department of the subsequent Nobel Prize winner, John R. Vane, at the Royal College of Surgeons. With a PhD from Bristol University (1976), he carried out postdoctoral research on prostaglandins and chronic inflammation with Ivan Bonta at Erasmus University Rotterdam, The Netherlands. He established laboratories in pharmacology and toxicology and was Director of Preclinical Discovery working on novel anti-inflammatory macrolides at GSK from 2006. From 2012 to 2019, Prof. Parnham built up preclinical research in the Fraunhofer Institute of Molecular Biology & Applied Ecology IME. Dr. Parnham has published and lectured extensively and organised symposia on various aspects of immunopharmacology and anti-inflammatory therapy and in 2015, received a Lifetime Achievement Award from the International Association of Inflammatory Societies (IAIS). He is a scientific advisor to several companies.